Immupharma Share Discussion Threads

[me ole china] 13/4/2022 09:37

Forget about at 11p placing


New forward selling happening now, aka new placing.

[me ole china] 13/4/2022 09:36

So what are you saying they funded this company and shortly the lost -50%?

would not sell then at lower loss?

[deanmatlazin] 13/4/2022 09:36

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce subscriptions and a placing to raise GBP3.55 million (the "Subscription(s)" and "Placing") through the issue of 32,272,727 new ordinary shares of 10 pence each in the Company ("Ordinary Shares") at a price of 11 pence per Ordinary Share

last placing - significant premium = 11p/share

[babbler] 13/4/2022 09:34

at 11p With warrants at 11p too.

[me ole china] 13/4/2022 09:34

Placing shares being dumped now at 60% profit.

Chasers getting impaled

[letmepass] 13/4/2022 09:31

true missed that., should do well from here

[babbler] 13/4/2022 09:18

they did a placing in December.

[ken chung] 13/4/2022 09:18

Lemmings chasing the price up even though the trial cannot start until late this year at the earliest and will take a couple of years to complete.Shorters getting ready for the kill.Lemmings and mushrooms only.

[guy_fawkes] 13/4/2022 09:16

The Gates WEF funded Convid kill shot never had a trial except on animals and they all died.
Now the Convid takers are dying from Immune system failure and AIDs related illness's.
Could this be their saviour.

[tomboyb] 13/4/2022 09:15

Hands and feet used to swell up every morning like balloons -

So lets see -

[tomboyb] 13/4/2022 09:14

I know someone that has Lupus and was very surprised at her diagnosis -

It can be incredibly dilapidating but is liveable, and entire life patterns have to change -

[kcowe] 13/4/2022 09:14

25 mill market cap .... this is a micro cap in the pharma world..

[letmepass] 13/4/2022 09:13

not much cash left though

[photon] 13/4/2022 09:12

Bottom line now is that this may yet prove to be a good option for patients. A much needed option. Trials outcomes prediction is not worthwhile, regardless of your position. We can now hope it will be positive for patients. That the balance between risk and reward has shifted positively today for investors is a side benefit.

[nobbygnome] 13/4/2022 09:11

>> super

Not sure what your point is....

[tomboyb] 13/4/2022 09:10

The next step is to take the asset into a phase III study in people with lupus, an autoimmune disease, and IIa/III assessment of its effects on sufferers of chronic inflammatory demyelinating polyneuropathy, a neurological disorder.

[nobbygnome] 13/4/2022 09:10

>> s_k

Yes but the fact they even contemplated giving it iv is significant as it suggests that is the only way they could get a full PK profile. Of course the pattern would be completely different when the drug is given sc so the results will be of limited use other than to get the half-life in blood.

[tomboyb] 13/4/2022 09:09

ImmuPharma drug clears a significant hurdle
Researchers have successfully completed a pharmacokinetic of the company's lead asset

mmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive, Tim McCarthy, described as a ‘significant milestone’ the successful completion of a pharmacokinetic (PK) study of its lead asset Lupuzor, also known as P140.

PK studies are there to assess how the body absorbs, distributes, metabolises, and excretes a compound.

In ImmuPharma’s case, the evaluation was mandated by the US Food & Drug Administration as part of the regulatory sign-off process.

Healthy volunteers were recruited and given a lower and higher dose of P140.

The read-out showed a ‘clear time and dose-related PK profile which is detectable in the blood’, investors were told.

The higher resulted in a ‘successful measurement of the absolute bioavailability of the drug’, the company added.

The read-out, which also showed P140 was safe and well-tolerated, tallied with the outcome predicted in-house.

The next step is to take the asset into a phase III study in people with lupus, an autoimmune disease, and IIa/III assessment of its effects on sufferers of chronic inflammatory demyelinating polyneuropathy, a neurological disorder.

The programmes will be led by ImmuPharma’s partner, Avion Pharmaceuticals.

ImmuPharma CEO McCarthy said: "We are delighted to be announcing this successful readout of the PK study.

“This is a significant milestone for ImmuPharma and for shareholders, and recognition of the key investment thesis behind ImmuPharma, in respect to having P140, a late-stage phase III clinical asset for the treatment of lupus patients with a phase IIa/III pivotal trial in CIDP close behind."

[ken chung] 13/4/2022 09:07

supernumerary, basically if there is nothing left in the bloodstream it is the same as a placebo, so basically just an expensive placebo by the look of it imo. Placebo might even work better and is certainly cheaper.

[babbler] 13/4/2022 09:06

ImmuPharma PLC said Wednesday that its lupus treatment Lupuzor/P140 met the required key endpoints in the pharmacokinetic study requested by the U.S. Food & Drug Administration.so the answer to your question is... yes. They are happy. Next...

[sicilian_kan] 13/4/2022 09:02

Nobby the 800 dose was given in both subcut and intravenous - see the rns

[supernumerary] 13/4/2022 09:00

Sorry Nobby, I thought when you said stuff like:

'So dosing starts on Feb 15th. They might as well finish by the 16th because there won't be any drug left in the body by then. The real question which remains unanswered is why have the FDA asked for this study to be completed and is the phase III dependent on results from this study to go ahead. If so what results are required. As I said the drug will be all gone by th second day and there will be nothing left for the remaiming 27days of the dosing cycle.'

you thought that it would disappear, as would any possible effects it might have. Seems not to be the case - Franklin says:

' also proved, in those models, that P140 continues to work long after it disappears from the plasma'.

My interest is in what the 'nothing left' actually is, because clearly there's something...

[ken chung] 13/4/2022 08:57

Fools chasing the price up, as shorters getting ready for the kill.No better than placebo imo.Lemmings and mushrooms only.